Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, currently trading at 55.2 HKD with a transaction volume of 18.0035 million HKD, following the announcement of orphan drug designation for its dual-specific antibody, Viligene (Oparatuzumab, LBL-024) for the treatment of pulmonary neuroendocrine carcinoma by the European Commission [1] Group 1 - Valiant Pharmaceuticals-B's stock rose by 4.94% to 55.2 HKD as of the report [1] - The company reported a transaction volume of 18.0035 million HKD [1] - The European Commission granted orphan drug designation for Viligene on January 22, 2026, marking a significant milestone in its global development [1] Group 2 - This designation follows the previous orphan drug recognition by the U.S. Food and Drug Administration (FDA) [1] - The dual-specific antibody Viligene is aimed at treating pulmonary neuroendocrine carcinoma [1] - The orphan drug designation is a critical step in the drug's development process, enhancing its potential marketability and support [1]

Group 1 - The core viewpoint is that the Chinese pharmaceutical industry has completed a transformation of growth drivers from 2015 to 2025, with innovation significantly opening new growth avenues for Chinese pharmaceutical companies [1] - The innovation sector in China has reached a scale where traditional pharmaceutical companies have successfully transformed, and their ability to expand internationally has accelerated, making them a key source of innovation for multinational pharmaceutical companies [1] - On the demand side, the aging population is accelerating, leading to increased demand for chronic disease management; on the payment side, health insurance revenue is steadily growing, and the National Healthcare Security Administration is actively promoting the development of commercial insurance to build a multi-tiered payment system [1] Group 2 - New technologies are accelerating industry transformation, with advancements in AI, brain-computer interfaces, early cancer screening, and AI healthcare rapidly developing [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on the research and development of new drugs driven by technological innovation [1] - The index emphasizes high R&D investment and innovation capability, favoring allocations in high-tech pharmaceutical sectors such as biopharmaceuticals and chemical pharmaceuticals to reflect market performance and development trends in these areas [1]

Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's strong management team and innovative drug pipeline focused on challenging RAS targets [1] Group 1: Product Pipeline and Innovation - The company has developed a diversified product pipeline centered around the difficult-to-drug RAS family members, leveraging deep understanding and successful R&D experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [2] - The product pipeline extends beyond RAS targets to include other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting market opportunities with favorable competitive landscapes [2] Group 2: Clinical Data and Competitive Advantage - The competitive advantage in RAS-targeted drug development is evident in the clinical data for GFH925 and GFH375, with GFH925 showing superior efficacy in 2L+ KRASG12C mutation NSCLC compared to overseas competitors and comparable or better results against domestic rivals [3] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, with promising preliminary data in third-line pancreatic cancer [3] - The dual antibody GDF15/IL-16 (GFS202A) shows early advantages in tolerability and activity compared to single-target drugs [3] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [4] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [4] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in China and overseas collaboration for GFH375 [5] - Based on a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x revenue peak sales multiple and an 87% potential upside [5] - Future focus includes monitoring the sales ramp-up of GFH925 post-reimbursement inclusion and additional data readouts from the RAS pipeline [5]

Core Viewpoint - The report by CMB International initiates coverage of Jinfang Pharmaceutical-B (02595) with a "Buy" rating and a target price of HKD 51, highlighting the company's innovative drug pipeline and strong management team [1] Group 1: Product Pipeline and Innovation - The company has established a diversified product pipeline focused on challenging RAS targets, leveraging deep understanding and successful development experience to create a candidate matrix that includes KRASG12C/G12D and pan-RAS, among others [1] - GFH925 (Fuzeracib) has been approved for marketing in mainland China, marking it as the first domestic product targeting the same RAS family member [1] - The product pipeline also extends to other significant indications such as tumors, cachexia, autoimmune, and inflammatory diseases, targeting promising areas like RIPK1 and GDF15/IL-6 [1] Group 2: Clinical Data and Competitive Advantage - The company demonstrates a competitive edge in RAS-targeted drug development, with GFH925 showing excellent efficacy in 2L+ KRASG12C mutation non-small cell lung cancer (NSCLC) patients, outperforming overseas competitors [2] - GFH375 is among the first globally to enter Phase III clinical trials for KRASG12D, showing promising initial data compared to major competitors [2] - The dual antibody GFS202A targeting GDF15/IL-16 is progressing rapidly, with early signs of tolerability and activity advantages over single-target drugs [2] Group 3: Management and Strategic Partnerships - The company has assembled a core management team with an average of over 20 years of industry experience, achieving a record of six years from project initiation to market launch for GFH925 [3] - The company actively seeks diverse global development opportunities and strategically selects partners to create value through complementary strengths, collaborating with notable firms such as Innovent Biologics, Merck, and Verastem [3] Group 4: Financial Projections and Valuation - The company is projected to achieve revenues of RMB 1.09 billion, 0.85 billion, and 1.18 billion in 2025-2027, primarily driven by sales of GFH925 in mainland China and overseas collaboration income from GFH375 [4] - Using a DCF valuation model, the target price of HKD 51 corresponds to a 2.3x peak revenue sales multiple and an 87% potential upside [4] - Future focus will be on the sales ramp-up of GFH925 post-inclusion in medical insurance and additional data readouts from the RAS pipeline [4]

Core Insights - Sinovac's inactivated hepatitis A vaccine, Hai'erlaifu®, has won the exclusive bid for the public market project in Oman for the 2026-2027 fiscal year, marking a significant achievement for the company in the Middle East and North Africa region [1] - Since entering the Omani market in 2022, Sinovac has established a reliable reputation based on consistent product quality, timely supply, and logistics support, which contributed to winning this exclusive supply qualification [1] - The Gulf Cooperation Council (GCC), a major political and economic organization in the Gulf region, has historically relied on multinational pharmaceutical companies for vaccine supplies, making Sinovac's success a notable breakthrough in gaining trust from GCC countries [1] Company Performance - Sinovac's Hai'erlaifu® vaccine has supplied over 130 million doses to nearly 50 countries and regions globally, making it one of the most widely used inactivated hepatitis A vaccines [1]

Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, reaching 55.2 HKD, following the announcement of orphan drug designation for its drug Valiant (Oparatuzumab, LBL-024) by the European Commission [1] Group 1 - On January 22, Valiant Pharmaceuticals-B announced that the European Commission granted orphan drug designation for its PD-L1/4-1BB bispecific antibody, Valiant, for the treatment of pulmonary neuroendocrine carcinoma [1] - This designation is a significant milestone, marking the second orphan drug designation for Valiant after receiving similar recognition from the U.S. Food and Drug Administration (FDA) [1] - The announcement reflects Valiant's progress in its global development efforts [1]

Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, currently trading at 55.2 HKD with a transaction volume of 18.0035 million HKD, following the announcement of orphan drug designation for its dual-specific antibody, Velesimab (LBL-024), by the European Commission [1] Group 1 - On January 22, Valiant Pharmaceuticals-B announced that the European Commission granted orphan drug designation for Velesimab (LBL-024) for the treatment of pulmonary neuroendocrine carcinoma [1] - This designation follows the previous orphan drug recognition by the U.S. Food and Drug Administration (FDA), marking a significant milestone in the global development process of Velesimab [1]

Core Viewpoint - Sinovac's seasonal flu vaccine has received official registration from the Ministry of Health and Prevention of the United Arab Emirates, marking a significant milestone for the company in expanding its vaccine portfolio and market reach [1]. Group 1: Company Developments - Sinovac's seasonal flu vaccine is now officially registered in the UAE, enhancing its credibility and market presence in the region [1]. - The vaccine has been widely used in over 20 countries and regions globally, indicating strong international demand and acceptance [1]. Group 2: Market Impact - The cumulative supply of Sinovac's seasonal flu vaccine has exceeded 120 million doses, showcasing the company's production capacity and distribution effectiveness [1].

Core Viewpoint - The sales of CAR-T cell therapy Carvykti (西达基奥仑赛) have significantly increased, but the stock price of Legend Biotech (传奇生物) has declined following the earnings report from Johnson & Johnson (强生) [1] Group 1: Financial Performance - Johnson & Johnson reported a total revenue of $94.193 billion for 2025, a year-on-year increase of 6% [1] - Carvykti generated $1.887 billion in revenue for 2025, representing a 95.95% increase compared to $963 million in 2024 [1] - In Q4 2025, Carvykti's sales reached $555 million, a 65.8% year-on-year increase, but only a 5.9% quarter-on-quarter growth [1] Group 2: Market Position and Product Development - Carvykti is positioned as a one-time therapy for relapsed or refractory multiple myeloma and has been approved in the U.S., EU, and Japan [3] - The product was priced at $465,000 per dose in the U.S., which is approximately three times the price of other domestic CAR-T products [3] - Legend Biotech aims to achieve profitability in 2026 by expanding Carvykti's application globally and increasing its use in community healthcare settings [4] Group 3: Production and Clinical Trials - Legend Biotech has completed the expansion of its production facility in Raritan, which is the largest CAR-T production base in the U.S., capable of supporting the treatment of up to 10,000 patients annually [4] - The company has initiated a Phase 3 clinical trial (CARTITUDE-6) for new indications targeting newly diagnosed multiple myeloma patients [4] Group 4: Market Challenges and Pricing - The commercialization of Carvykti in China lagged behind the U.S. market by two years, with approval granted in August 2024 [7] - The pricing strategy for the Chinese market has not yet been disclosed, and the product has not participated in national health insurance negotiations [7] - The high costs associated with CAR-T therapies pose challenges for accessibility, despite ongoing efforts to explore diverse payment models [8][9]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [5]. Core Insights - The company is leading the ADC (Antibody-Drug Conjugate) innovation wave and is expected to achieve commercialization by 2026 [2][3]. - The company has received IND approval for its self-developed ADAM9 ADC drug DB-1317, allowing clinical trials in late-stage metastatic solid tumor patients [2]. - The HER2 ADC DB-1303 has reached its primary endpoint in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer, accelerating its market approval process [3]. - The company is expected to report multiple clinical data readouts in 2026, which could significantly impact its growth trajectory [9]. Financial Forecasts - Projected revenues for 2024, 2025, 2026, and 2027 are 1,941 million, 1,950 million, 1,972 million, and 2,100 million RMB respectively, with growth rates of 8.7%, 0.5%, 1.1%, and 6.5% [4]. - The net profit attributable to shareholders is forecasted to be -1,050 million, -247 million, -386 million, and -341 million RMB for the same years, reflecting growth rates of -193.8%, 76.5%, -56.1%, and 11.5% [4]. - Earnings per share (EPS) are expected to be -11.75, -2.76, -4.31, and -3.82 RMB for 2024, 2025, 2026, and 2027 respectively [4]. Clinical Development and Pipeline - The company is advancing its ADC pipeline, including DB-1316, which aims to address existing ADC resistance issues and is set to enter clinical stages soon [9]. - Collaborations with BioNtech are expected to yield significant clinical data in 2026, enhancing the company's competitive position in the ADC market [9].